On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial
Study limitation reported by the research below: “TACE-PFS is a surrogate endpoint specific to this trial; it is not a universally standardised oncology endpoint, which may complicate cross-trial comparisons.”